Mechanism of action<unk>  inhibits multiple histone deacetylase enzymes, a mechanism leading to apoptosis of malignant cells via multiple pathways. Pharmacokinetics<unk>  is absorbed quickly and almost completely from the gut, but has a significant first-pass effect, resulting in a total bioavailability of 21%. Highest blood plasma levels in patients with advanced cancer are reached after two hours. Plasma protein binding is about 90%. The substance is metabolised mainly through oxidation by the liver enzyme CYP3A4 and to a small extent by CYP2D6 and CYP2C19. It is also reduced, hydrolyzed and glucuronidized by unspecified enzymes. All metabolites seem to be inactive. Biological half-life is estimated to be 37 hours. 29–51% are excreted via the urine and 44–77% via the faeces.
Panobinostat
Martinostat
Olaparib
Rucaparib
Teprotumumab
Vorinostat
Palbociclib
Dabrafenib